menu
    • menu
    [{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"RNA","graph1":"Oncology","graph2":"Discovery","graph3":"858 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"858 Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"858 Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETX-19477","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"858 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"858 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"858 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"ETX-19477","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"858 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"858 Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"6","companyTruncated":"858 Therapeutics \/ Avidity Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by 858 Therapeutics

    Menu

    858 Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            858 Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            858 Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETX-19477

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Avidity Partners

                            Deal Size : $50.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            858 Therapeutics Announces $50 Million Series B Financing

                            Details : The financing aims to support the ongoing clinical development of PARG inhibitor ETX-19477, which is being evaluated in early-stage clinical studies for cancer treatment.

                            Product Name : ETX-19477

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 26, 2024

                            Lead Product(s) : ETX-19477

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Avidity Partners

                            Deal Size : $50.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            858 Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            858 Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETX-19477

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR 2024 Annual Meeting

                            Details : ETX-19477 is a potent PARG inhibitor in development for multiple solid tumors, crucial for DNA repair mechanisms.

                            Product Name : ETX-19477

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 14, 2024

                            Lead Product(s) : ETX-19477

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            858 Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            858 Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Versant Ventures

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

                            Details : Proceeds are being used to develop a portfolio of small molecules directed against novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 21, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Versant Ventures

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth